Spatial Distribution and Prognostic Implications of Tumor-Infiltrating FoxP3– CD4+ T Cells in Biliary Tract Cancer
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose The clinical implications of tumor-infiltrating T cell subsets and their spatial distribution in biliary tract cancer (BTC) patients treated with gemcitabine plus cisplatin were investigated. Materials and Methods A total of 52 BTC patients treated with palliative gemcitabine plus cisplatin were included. Multiplexed immunohistochemistry was performed on tumor tissues, and immune infiltrates were separately analyzed for the stroma, tumor margin, and tumor core. Results The density of CD8+ T cells, FoxP3– CD4+ helper T cells, and FoxP3+ CD4+ regulatory T cells was significantly higher in the tumor margin than in the stroma and tumor core. The density of LAG3– or TIM3-expressing CD8+ T cell and FoxP3– CD4+ helper T cell infiltrates was also higher in the tumor margin. In extrahepatic cholangiocarcinoma, there was a higher density of T cell subsets in the tumor core and regulatory T cells in all regions. A high density of FoxP3– CD4+ helper T cells in the tumor margin showed a trend toward better progression-free survival (PFS) (p=0.092) and significantly better overall survival (OS) (p=0.012). In multivariate analyses, a high density of FoxP3– CD4+ helper T cells in the tumor margin was independently associated with favorable PFS and OS. Conclusion The tumor margin is the major site for the active infiltration of T cell subsets with higher levels of LAG3 and TIM3 expression in BTC. The density of tumor margin-infiltrating FoxP3– CD4+ helper T cells may be associated with clinical outcomes in BTC patients treated with gemcitabine plus cisplatin.
Abstract
Purpose The clinical implications of tumor-infiltrating T cell subsets and their spatial distribution in biliary tract cancer (BTC) patients treated with gemcitabine plus cisplatin were investigated. Materials and Methods A total of 52 BTC patients treated with palliative gemcitabine plus cisplatin were included. Multiplexed immunohistochemistry was performed on tumor tissues, and immune infiltrates were separately analyzed for the stroma, tumor margin, and tumor core. Results The density of CD8+ T cells, FoxP3– CD4+ helper T cells, and FoxP3+ CD4+ regulatory T cells was significantly higher in the tumor margin than in the stroma and tumor core. The density of LAG3– or TIM3-expressing CD8+ T cell and FoxP3– CD4+ helper T cell infiltrates was also higher in the tumor margin. In extrahepatic cholangiocarcinoma, there was a higher density of T cell subsets in the tumor core and regulatory T cells in all regions. A high density of FoxP3– CD4+ helper T cells in the tumor margin showed a trend toward better progression-free survival (PFS) (p=0.092) and significantly better overall survival (OS) (p=0.012). In multivariate analyses, a high density of FoxP3– CD4+ helper T cells in the tumor margin was independently associated with favorable PFS and OS. Conclusion The tumor margin is the major site for the active infiltration of T cell subsets with higher levels of LAG3 and TIM3 expression in BTC. The density of tumor margin-infiltrating FoxP3– CD4+ helper T cells may be associated with clinical outcomes in BTC patients treated with gemcitabine plus cisplatin.
참고문헌 (30)
- Valle J, "Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer", N Engl J Med, 362, pp.1273~1281 (2010)
- Chae H, "Therapeutic relevance of targeted sequencing in management of patients with advanced biliary tract cancer : DNA damage repair gene mutations as a predictive biomarker", Eur J Cancer, 120, pp.31~39 (2019)
- Abou-Alfa GK, "Ivosidenib in IDH1-mutant, chemotherapyrefractory cholangiocarcinoma(ClarIDHy) : a multicentre, randomised, double-blind, placebo-controlled, phase 3 study", Lancet Oncol, 21, pp.796~807 (2020)
- Abou-Alfa GK, "Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma : a multicentre, open-label, phase 2 study", Lancet Oncol, 21, pp.671~684 (2020)
- Yoo C, "Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-beta and PD-L1, in patients with pretreated biliary tract cancer", J Immunother Cancer, 8, pp.e000564~ (2020)
- Ueno M, "Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer : a non-randomised, multicentre, open-label, phase 1 study", Lancet Gastroenterol Hepatol, 4, pp.611~621 (2019)
- Piha-Paul SA, "Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer : results from the KEYNOTE-158and KEYNOTE-028 studies", Int J Cancer, 147, pp.2190~2198 (2020)
- 강준호, "Efficacy and Safety of Pembrolizumab in Patients with Refractory Advanced Biliary Tract Cancer: Tumor Proportion Score as a Potential Biomarker for Response", Cancer Research and Treatment, 52(2), pp.594~603 (2020), 대한암학회
- Waldman AD, "A guide to cancer immunotherapy : from T cell basic science to clinical practice", Nat Rev Immunol, 20, pp.651~668 (2020)
- Borst J, "CD4(+)T cell help in cancer immunology and immunotherapy", Nat Rev Immunol, 18, pp.635~647 (2018)
- Togashi Y, "Regulatory T cells in cancer immunosuppression : implications for anticancer therapy", Nat Rev Clin Oncol, 16, pp.356~371 (2019)
- Kitano Y, "Tumour-infiltrating inflammatory and immune cells in patients with extrahepatic cholangiocarcinoma", Br J Cancer, 118, pp.171~180 (2018)
- Goeppert B, "Prognostic impact of tumourinfiltrating immune cells on biliary tract cancer", Br J Cancer, 109, pp.2665~2674 (2013)
- Massi D, "The density and spatial tissue distribution of CD8(+)and CD163(+)immune cells predict response and outcome in melanoma patients receiving MAPK inhibitors", J Immunother Cancer, 7, pp.308~ (2019)
- Tumeh PC, "PD-1 blockade induces responses by inhibiting adaptive immune resistance", Nature, 515, pp.568~571 (2014)
- Godet Y, "Analysis of spontaneous tumor-specific CD4T-cell immunity in lung cancer using promiscuous HLA-DR telomerase-derived epitopes : potential synergistic effect with chemotherapy response", Clin Cancer Res, 18, pp.2943~2953 (2012)
- Yuan Y, "Spatial heterogeneity in the tumor microenvironment", Cold Spring Harb Perspect Med, 6, pp.a026583~ (2016)
- Heindl A, "Mapping spatial heterogeneity in the tumor microenvironment : a new era for digital pathology", Lab Invest, 95, pp.377~384 (2015)
- Kather JN, "Topography of cancer-associated immune cells in human solid tumors", Elife, 7, pp.e36967~ (2018)
- Kim BJ, "Prognostic factors in patients with advanced biliary tract cancer treated with first-line gemcitabine plus cisplatin : retrospective analysis of 740 patients", Cancer Chemother Pharmacol, 80, pp.209~215 (2017)
- Christgen M, "The region-of-interest size impacts on Ki67 quantification by computer-assisted image analysis in breast cancer", Hum Pathol, 46, pp.1341~1349 (2015)
- Thorsson V, "The immune landscape of cancer", Immunity, 48, pp.812~830 (2018)
- Kim HD, "Association between expression level of PD1 by tumorinfiltrating CD8(+)T cells and features of hepatocellular carcinoma", Gastroenterology, 155, pp.1936~1950 (2018)
- Kim HD, "4-1BB delineates distinct activation status of exhausted tumor-infiltrating CD8(+)T cells in hepatocellular carcinoma", Hepatology, 71, pp.955~971 (2020)
- Oh DY, "Intratumoral CD4(+)T cells mediate anti-tumor cytotoxicity in human bladder cancer", Cell, 181, pp.1612~1625 (2020)
- Takagi S, "Dendritic cells, T-cell infiltration, and Grp94expression in cholangiocellular carcinoma", Hum Pathol, 35, pp.881~886 (2004)
- Jackaman C, "Chemotherapy broadens the range of tumor antigens seen by cytotoxic CD8(+)T cells in vivo", Cancer Immunol Immunother, 61, pp.2343~2356 (2012)
- Ding ZC, "Cytotoxic chemotherapy and CD4+ effector T cells : an emerging alliance for durable antitumor effects", Clin Dev Immunol, 2012, pp.890178~ (2012)
- Soh JS, "Immunoprofiling of colitis-associated and sporadic colorectal cancer and its clinical significance", Sci Rep, 9, pp.6833~ (2019)
- Hofman P, "Multiplexed immunohistochemistry for molecular and immune profiling in lung cancer-just about ready for prime-time?", Cancers(Basel), 11, pp.283~ (2019)